Scarica l'app Stockscreener
13.79
0.55%
0.075
Dopo l'orario di chiusura:
13.79
0.005
+0.04%
Precedente Chiudi:
$13.71
Aprire:
$13.49
Volume 24 ore:
490.31K
Relative Volume:
0.59
Capitalizzazione di mercato:
$639.32M
Reddito:
-
Utile/perdita netta:
$-161.15M
Rapporto P/E:
-3.7107
EPS:
-3.7149
Flusso di cassa netto:
$-138.61M
1 W Prestazione:
+4.91%
1M Prestazione:
+13.18%
6M Prestazione:
-27.33%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$13.19
$14.04
Intervallo di 1 settimana:
$13.00
$14.22
Portata 52W:
$9.10
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Nome
Maplight Therapeutics Inc
Settore
Industria
Telefono
650-839-4360
Indirizzo
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
13.79 | 635.84M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Needham | Buy |
| 2026-04-07 | Iniziato | TD Cowen | Buy |
| 2026-03-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-11-21 | Iniziato | Jefferies | Buy |
| 2025-11-21 | Iniziato | Leerink Partners | Outperform |
| 2025-11-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-21 | Iniziato | Stifel | Buy |
Mostra tutto
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
MapLight Therapeutics to Participate in Upcoming Investor Conference - The Manila Times
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - Stocktwits
Raymond James initiates coverage on MapLight Therapeutics with Strong Buy - scanx.trade
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 5.3%Here's What Happened - MarketBeat
Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com Canada
Maplight Therapeutics (NASDAQ:MPLT) Price Target Lowered to $43.00 at Needham & Company LLC - MarketBeat
Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
5AM Venture Management LLC Makes New Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 4.6%What's Next? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading 7.8% HigherShould You Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire
Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat
MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - Stock Titan
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
MapLight Therapeutics (MPLT) grants CSO new options and RSUs - Stock Titan
MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet
Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan
MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Therapeutics announces $150M private placement - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - Moomoo
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
MapLight Therapeutics Announces $150 Million Private Placement Financing - marketscreener.com
MapLight bags USD 150m after muscarinic schizophrenia Phase II win - AllSci
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside - TradingView
Dividend HistoryMapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Reports Positive Phase 2 Schizophrenia Data, Plans Phase 3 Trial - Minichart
Needham raises MapLight Therapeutics price target to $45 - scanx.trade
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028 - scanx.trade
MapLight Therapeutics Secures $150 Million Through Private Stock Placement - Kalkine Media
MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenses - Kalkine Media
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal - Stock Titan
MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary - TradingView
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4%Here's Why - MarketBeat
Latham Advises on MapLight Therapeutics’ US$150 Million Private Placement Financing - Latham & Watkins LLP
MapLight Therapeutics secures $150 million financing - The Pharma Letter
MapLight Therapeutics stock jumps on $150M private placement By Investing.com - Investing.com Nigeria
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics raises $150 million in private placement - Investing.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com South Africa
Zealand’s royalty deal; Khartis raises money for TED drug - Endpoints News
MapLight Therapeutics stock jumps on $150M private placement - Investing.com India
MapLight Therapeutics Launching $150 Million Private Placement Financing - marketscreener.com
Maplight Therapeutics Inc Azioni (MPLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):